A Phase III, Multicenter, Open Label, Extension Study to Evaluate the Long-Term Safety of Renzapride 4 mg Once Daily in Women With Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Latest Information Update: 05 Jan 2017
At a glance
- Drugs Renzapride (Primary)
- Indications Irritable bowel syndrome
- Focus Adverse reactions
- Sponsors Alizyme
- 05 Jan 2017 New trial record